home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cytodyn Inc (OP:CYDY)

0.3459 UNCHANGED

Streaming Delayed Price Updated: 3:58 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 5 Next >

CytoDyn Announces President Takes Medical Leave of Absence

May 24, 2023

From CytoDyn Inc.

Via GlobeNewswire

CytoDyn to Hold Webcast to Provide a Company Update

April 05, 2023

From CytoDyn Inc.

Via GlobeNewswire

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗

January 17, 2023

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...

Via Benzinga

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

December 23, 2022

From CytoDyn Inc.

Via GlobeNewswire

OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes ↗

December 13, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.

Via Benzinga

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

November 22, 2022

From CytoDyn Inc.

Via GlobeNewswire

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

October 28, 2022

From CytoDyn Inc.

Via GlobeNewswire

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗

October 27, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.

Via Benzinga

CytoDyn Announces Appointment of Additional Directors with Industry Experience

October 20, 2022

From CytoDyn Inc.

Via GlobeNewswire

OTC Markets' Most Active Securities Sees A Shake-up In July ↗

August 16, 2022

July gave world markets a breather from 2022’s poor financial conditions.

Via Benzinga

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

August 11, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

August 10, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month ↗

August 05, 2022

The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share...

Via Benzinga

Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June ↗

July 18, 2022

Reflecting the expected conditions of a bear market, many of the world’s indices saw a decrease in price throughout June.

Via Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗

March 31, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY

March 18, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators ↗

February 14, 2022

Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

January 25, 2022

From CytoDyn Inc.

Via Business Wire

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

January 13, 2022

From CytoDyn Inc.

Via Business Wire

Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects

January 10, 2022

From CytoDyn Inc.

Via Business Wire

Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose

January 05, 2022

From CytoDyn Inc.

Via Business Wire

Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant ↗

December 29, 2021

Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The...

Via Benzinga

CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO

December 22, 2021

From CytoDyn Inc.

Via Business Wire

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population

December 21, 2021

From CytoDyn Inc.

Via Business Wire

NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients

December 13, 2021

From CytoDyn Inc.

Via Business Wire

CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population

December 09, 2021

From CytoDyn Inc.

Via Business Wire

CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients

December 09, 2021

From CytoDyn Inc.

Via Business Wire

CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022

December 08, 2021

From CytoDyn Inc.

Via Business Wire

CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission

December 01, 2021

From CytoDyn Inc.

Via Business Wire

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow

November 29, 2021

From CytoDyn Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com